Literature DB >> 29319687

First in vivo human genome editing trial.

.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29319687     DOI： 10.1038/nbt0118-5b

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  6 in total

1.  Positron emission tomography reporter gene strategy for use in the central nervous system.

Authors:  Tom Haywood; Corinne Beinat; Gayatri Gowrishankar; Chirag B Patel; Israt S Alam; Surya Murty; Sanjiv Sam Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-23       Impact factor: 11.205

Review 2.  Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich's Ataxia.

Authors:  Anusha Sivakumar; Stephanie Cherqui
Journal:  Front Genome Ed       Date:  2022-05-17

Review 3.  In Vivo Genome Editing as a Therapeutic Approach.

Authors:  Beatrice Xuan Ho; Sharon Jia Hui Loh; Woon Khiong Chan; Boon Seng Soh
Journal:  Int J Mol Sci       Date:  2018-09-12       Impact factor: 5.923

Review 4.  From scientific discovery to treatments for rare diseases - the view from the National Center for Advancing Translational Sciences - Office of Rare Diseases Research.

Authors:  Petra Kaufmann; Anne R Pariser; Christopher Austin
Journal:  Orphanet J Rare Dis       Date:  2018-11-06       Impact factor: 4.123

Review 5.  The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease.

Authors:  Luis A Martinez Velazquez; Brian G Ballios
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

Review 6.  In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges.

Authors:  Alessio Cantore; Alessandro Fraldi; Vasco Meneghini; Angela Gritti
Journal:  Front Med (Lausanne)       Date:  2022-01-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.